The 2023-2028 World Outlook for Influenza Vaccines
This study covers the world outlook for influenza vaccines across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.
In this report we define the sales of influenza vaccines as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Advisory Committee for Immunization Practices, Astellas Pharma, AstraZeneca, Bharat Immunologicals and Biologicals Corporation, Binnopharm, Bio Farma, BioDiem, BioManguinhos/Oswaldo Cruz Foundation, Biondvax, Bionor, Biremx, Brazilian Ministry of Health, Bristol-Myers Squibb, Butantan Institute, Cabtacuzino Institute, Center for Biologics Evaluation and Research, Centre for Disease Control and Prevention, Chemo-Sero-Therapeutic Research Institute, China National Biotech Group, Chinese Food and Drug Administration, Clearpath, CSL, CureVac, Daiichi Sankyo, Developing Countries Vaccine Manufacturers Network (DCVMN), Dynavax, Emergent Bio Solution, Inc., F. Hoffmann-La Roche, Flanders Institute, Food and Drug Administration (FDA), FORT, Fresenius Pharmaceuticals, Gamma Vaccines, Gavi Alliance, Glaxo Smith Klein, GlaxoWellcome, Global Influenza Programme, Governmental Pharmaceutical Organization (GPO), Green Cross, Grippol, Health Service Bureau, Japan, Hualan Bio, Immune Targeting Systems, Indian Association of Paediatrics, International Vaccine Access Center (IVAC), Janssen Pharmaceuticals, Jenner Institute, University of Oxford, Johnson & Johnson, Krka Pharmaceuticals, Medicago, Medicare, Medicines and Healthcare products Regulatory Agency (MHRA), MedImmune, Merck, Mitsubishi Tanabe Pharma, MSD Pharmaceuticals, National Health Service, UK, Netherlands Vaccine Institute, Novartis, Organisation for Economic Co-operation And Development, Panacea Biotech, Partnership for Influenza Vaccine Introduction, Petrovax, Pfizer, Protein Science, Razi Institute, Revlon, Roche Pharmaceuticals, Sanofi, Seqirus, Serum Institute of India (SLL), Servizio Sanitario Nationale, Shionogi Pharmaceuticals, Sinopharm, Sinovac Biotech, Sistema Unico de Saude, SmithKline Beecham, Takeda Pharmaceuticals, Terumo Pharmaceuticals, The Ministry of Health, Labour and Welfare, Japan, Torlak Institut, Ultriks, US Department of Health and Human Services, Vacsera, Valeant Pharmaceuticals, VaxInnate, WHO Strategic Advisory Group of Experts, and World Health Organization. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook